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Background Coronary inflammation induces dynamic changes in the balance between water and lipid content in perivascular
adipose tissue (PVAT), as captured by perivascular Fat Attenuation Index (FAI) in standard coronary CT angiog-
raphy (CCTA). However, inflammation is not the only process involved in atherogenesis and we hypothesized that
additional radiomic signatures of adverse fibrotic and microvascular PVAT remodelling, may further improve car-
diac risk prediction.
...................................................................................................................................................................................................
Methods
and results
We present a new artificial intelligence-powered method to predict cardiac risk by analysing the radiomic profile
of coronary PVAT, developed and validated in patient cohorts acquired in three different studies. In Study 1, adi-
pose tissue biopsies were obtained from 167 patients undergoing cardiac surgery, and the expression of genes rep-
resenting inflammation, fibrosis and vascularity was linked with the radiomic features extracted from tissue CT
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images. Adipose tissue wavelet-transformed mean attenuation (captured by FAI) was the most sensitive radiomic
feature in describing tissue inflammation (TNFA expression), while features of radiomic texture were related to adi-
pose tissue fibrosis (COL1A1 expression) and vascularity (CD31 expression). In Study 2, we analysed 1391 coronary
PVAT radiomic features in 101 patients who experienced major adverse cardiac events (MACE) within 5 years of
having a CCTA and 101 matched controls, training and validating a machine learning (random forest) algorithm (fat
radiomic profile, FRP) to discriminate cases from controls (C-statistic 0.77 [95%CI: 0.62–0.93] in the external valid-
ation set). The coronary FRP signature was then tested in 1575 consecutive eligible participants in the SCOT-
HEART trial, where it significantly improved MACE prediction beyond traditional risk stratification that included
risk factors, coronary calcium score, coronary stenosis, and high-risk plaque features on CCTA (D[C-statistic] =
0.126, P< 0.001). In Study 3, FRP was significantly higher in 44 patients presenting with acute myocardial infarction
compared with 44 matched controls, but unlike FAI, remained unchanged 6 months after the index event, confirm-
ing that FRP detects persistent PVAT changes not captured by FAI.
...................................................................................................................................................................................................
Conclusion The CCTA-based radiomic profiling of coronary artery PVAT detects perivascular structural remodelling associated
with coronary artery disease, beyond inflammation. A new artificial intelligence (AI)-powered imaging biomarker
(FRP) leads to a striking improvement of cardiac risk prediction over and above the current state-of-the-art.
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Introduction
Coronary artery disease (CAD) remains a leading cause of morbidity
and mortality despite advances in primary and secondary prevention
strategies.1 Coronary CT angiography (CCTA) is now a first line in-
vestigation for the assessment of possible CAD.2–4 The CCTA trad-
itionally relies on the detection of obstructive lesions or coronary
calcification to guide cardiovascular risk stratification and clinical deci-
sion-making.5,6 However, optimal medical therapy and clinical risk
factor management do not always prevent acute coronary syn-
dromes, resulting in the concept of ‘residual cardiovascular risk’, a
major factor driving uncertainty in risk stratification and targeting of
healthcare interventions.7,8 Vascular inflammation, in particular, is
recognized as a major contributor to both atherosclerotic plaque for-
mation and destabilization.7,8 However, conventional tests such as
circulating inflammatory biomarkers are not specific enough to iden-
tify coronary inflammation, and advanced imaging tests (e.g. positron
emission tomography-CT using 18F-NaF)9,10 are costly and not wide-
ly available, limiting their current use in clinical practice.11,12
It is now established that the coronary artery wall and its perivas-
cular adipose tissue (PVAT) interact in a bidirectional manner.12–15
We have recently demonstrated that, in the presence of vascular in-
flammation, the release of pro-inflammatory molecules from the dis-
eased vascular wall inhibits differentiation and lipid accumulation in
PVAT pre-adipocytes, creating a gradient from a lipid-rich and less
aqueous phase close to a non-diseased artery to lipid-poor and more
aqueous phase close to an inflamed artery.12 In humans, this
inflammation-induced gradient of PVAT composition leads to an in-
crease in the CT attenuation from more negative [closer to -190
Hounsfield Units (HU)] to less negative (closer to -30 HU) values, as
captured by the recently described perivascular Fat Attenuation
Index (FAI).12 The FAI is a sensitive and dynamic biomarker of
coronary inflammation12 and is a strong and independent
predictor of adverse cardiac events.16 Furthermore, in the CRISP-CT
(Cardiovascular RIsk Prediction using Computed Tomography)
study,16 the prognostic value of FAI was reduced among patients
who initiated treatment with aspirin and statin therapy after CCTA,
suggesting that the risk identified by this biomarker may be
modifiable.
However, chronic atherosclerosis and vascular inflammation may
also be associated with structural changes in the adjacent adipose tis-
sue, including fibrosis and microvascular remodelling.17,18 An imaging
biomarker detecting these changes in PVAT composition could have
important clinical implications for CAD diagnosis and treatment by
supplementing the inflammatory burden detected by FAI. Advances
in computational radiomic approaches and machine learning now en-
able the extraction of large amounts of quantitative information from
imaging data using specific data-characterization algorithms, thus
Translational perspectives
Perivascular adipose tissue (PVAT) changes its composition in response to coronary inflammation, as demonstrated by the perivascular Fat
Attenuation Index (FAI) derived from coronary computed tomography angiography. A novel radiotranscriptomic signature of PVAT texture
detects additional disease-related changes to PVAT composition, including fibrotic and microvascular remodelling. The fat radiomic profile
(FRP), derived by machine learning-powered radiomic analysis of PVAT remodelling, significantly improves risk prediction for adverse cardiac
events beyond the current state-of-the-art. Whereas FAI changes dynamically in response to acute coronary inflammation, FRP captures per-
sistent structural remodelling in PVAT and provides additional risk stratification in both primary and secondary prevention.
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..identifying imaging patterns of significant clinical value that cannot be
recognized by a human reader.19 Linking such imaging patterns to
underlying tissue biology and gene expression status in a ‘radiotran-
scriptomic’ approach could lead to a more individualized assessment
of disease activity in patients undergoing CCTA, and could provide
new biological insights in to disease mechanisms.
We hypothesized that comprehensive CCTA-based radiomic
phenotyping of coronary PVAT may reveal new biomarkers of adverse
remodelling in response to coronary inflammation and atherosclerosis.
Methods
Study design
The patient demographics and relevant clinical characteristics for each
study are presented in the Supplementary material online, Tables S1–S4).
A comprehensive workflow diagram of each study design is presented in
Figure 1. All studies complied with the Declaration of Helsinki and were
approved by local ethics committees. Informed consent was obtained
from all participants.
Study 1
To understand how fibrosis and vascularity of adipose tissue are visual-
ized using CT, 167 patients scheduled to undergo cardiac surgery
underwent CCTA and biopsies of adipose tissue were obtained during
surgery. The CT radiomic profile of adipose composition was quantified
and, using a radiotranscriptomic approach, was subsequently linked to
the expression of genes characterizing inflammation (e.g. tumour necrosis
factor a, TNFA),12,20 fibrosis (e.g. COL1A1),21 and vascularity [e.g.
endothelial-marker platelet and endothelial cell adhesion marker CD31
(PECAM1)]22 within the visualized tissue. The study was approved by the
local Research Ethics Committee (Oxford REC C 11/SC/0140).
Study 2
To train and subsequently validate a radiomic signature of global coronary
PVAT that identifies individuals at increased risk for major adverse cardiac
events (MACE), and compare it with the radiotranscriptomic signatures
of inflammation, fibrosis and vascularity, we designed a case-control study
of patients with a MACE (defined as the composite endpoint of cardiac
mortality and non-fatal myocardial infarction, n= 101) within 5 years of a
CCTA scan vs. controls who had no cardiac event during the same
follow-up period after a CCTA [matched 1:1 for age, gender, risk factors,
scanner, location (cohort) and acquisition settings (kVp)]. Both cases and
controls were retrieved from the pool of 5487 patients with CCTA who
participated either in the Cardiovascular RISk Prediction with CT
(CRISP-CT) study16 or the Scottish COmputed Tomography of the
HEART (SCOT-HEART) trial.23,24 The study design, collection of demo-
graphic data, clinical information, and outcomes for both cohorts have
been previously described (Supplementary material online).16,23,24 The
Study 1
Idenfy CT radiomic features to 
best describe the transcriptomic 
proﬁle of human adipose ssue  
167 paents undergoing
cardiac surgery
Study 2
Building and 
externally 
validang the FRP 
(see Figure 4)
Radiotranscriptomic analysis: 
linking CT radiomic features to 
adipose ssue inﬂammaon, 
ﬁbrosis and vascularity  
Case-control 
nested study of 
101 MACE cases 
and 101 matched 
controls
44 AMI paents
44 stable CAD controls 
Study 3
AI
M
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RT
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ES FRP phenotyping 
at baseline ±
six months aer 
AMI 
1,575 
consecuve 
individuals 
undergoing 
CCTA in 
SCOT-HEART 
trial
Cohort-wide 
tesng of FRP 
performance vs 
standard of care
• 167 adipose ssue biopsies 
for transcripon studies
• CT images for radiomic 
feature extracon
To develop & validate the peri-
coronary FRP signature to predict 
MACE in 5487 parcipants in the
CRISP-CT & SCOTHEART studies
Evaluate the ability of FRP to 
detect unstable coronary 
plaques and track changes over 
6 months post-AMI in 88 
paents from the ORFAN and 
ox-IMPACT studies  
Figure 1 Workflow diagram. Study 1 included 167 adipose tissue biopsies from cardiac surgery patients in order to evaluate the correlation be-
tween fat biology and radiomic features. Study 2 utilized a pool of 5487 patients with coronary CT angiography who participated either in the
Cardiovascular RISk Prediction using CT study or the SCOT-HEART trial, so as to develop and validate FRP, and finally to test its cohort-wide per-
formance against the standard of care. Finally, in Study 3, we performed further external biological validation of FRP as follows: 88 patients from the
Ox-IMPACT and ORFAN studies were included to test FRP’s ability to identify acute myocardial infarction-related perivascular changes and compare
its ability to track longitudinal perivascular changes over a period of 6 months with that of Fat Attenuation Index. AMI, acute myocardial infarction;
CAD, coronary artery disease; CRISP-CT, Cardiovascular RISk Prediction using CT study; FRP, fat radiomic profile; ORFAN, Oxford Risk Factors
and Non-invasive Imaging study; Ox-IMPACT, Oxford Imaging of Perivascular Adipose tissue using Computed Tomography study; SCOT-HEART,
Scottish COmputed Tomography of the HEART study.
Perivascular fat radiomic profile and cardiac risk 3
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pooling of CCTA scans from multiple imaging centres with variable hard-
ware and CCTA protocols (see Supplementary material online) was per-
formed to facilitate the discovery of radiomic patterns that are less likely
to be confounded by scanner- or centre-specific variables and are more
likely to be generalizable and valid across different centres and CT scan-
ner types. The selected scans were then randomly split into a training//in-
ternal validation (80%) and an external validation set (20%) to train and
validate a high-risk PVAT radiomic signature (fat radiomic profile, FRP)
that can discriminate high-risk MACE from low-risk non-MACE cases.
Once this signature (FRP) was trained and tested in the external valid-
ation set, its cohort-wide performance for detection of residual cardiac risk
was explored in 1575 consecutive eligible patients from the SCOT-
HEART trial (SCOT-HEART, NCT01149590), a population in which
CCTA [as well as non-contrast cardiac CT for Agatston coronary calcium
scoring (CCS)] was used to guide changes in clinical care. The aim was to
explore whether this radiomic signature could add value in cardiac risk
prediction over and above traditional risk factors and detect a residual
risk not modified by subsequent interventions (Supplementary material
online). The median follow-up period was 4.8 years (interquartile range:
4.2–5.7 years), and adverse cardiac events, including death, non-fatal acute
myocardial infarction (AMI) and revascularization events were recorded
as described previously.23,24
Study 3
To compare the ability of FRP to track perivascular changes related to
AMI in comparison to the inflammation-based FAI-index, a total of 44
AMI patients underwent CCTA within 96 h of presentation ± follow-up
CCTA after six event-free months, as part of a prospective study aiming
to assess the association between vulnerable plaques and pericoronary
fat radiomic features [Oxford Imaging of Perivascular Adipose tissue using
Computed Tomography (Ox-IMPACT) study, Research Ethics
Committee Reference 17/SC/0058].25,26 A total of 44 matched patients
with stable CAD were selected as the control group [Oxford Risk
Factors and non-invasive Imaging (ORFAN) study; Research Ethics
Committee Reference 15/SC/0545].
Coronary CTangiography protocol, data
collection and definitions
The detailed CCTA protocols for image acquisition are presented in the
Supplementary material online and in previously published stud-
ies.12,16,23,24 Coronary artery stenosis assessment and the presence of
high-risk plaque (HRP) features (defined as the presence of at least one of
the following: low-attenuation plaque, positive remodelling, napkin-ring
sign or spotty calcification) were performed as previously described
(Supplementary material online).27,28
Radiomic analysis
Image transfer and segmentation
All images were first anonymized locally and subsequently transferred to
the Oxford Academic Cardiovascular Computed Tomography
(OXACCT) core lab (Oxford, UK) for analysis on a dedicated worksta-
tion by investigators blinded to population demographics and outcomes.
All analyses were performed using the standard operating procedures of
the OXACCT core lab and for FRP measurements both intra-observer
[intra-class correlation coefficient (ICC) 0.995 (95% CI: 0.982–0.999),
P< 0.001] and inter-observer agreement amongst three independent
operators [ICC 0.938 (95% CI: 0.861–0.977), P< 0.001] was excellent.
Subcutaneous adipose tissue (Study 1) was segmented on three consecu-
tive axial slices at the caudal end of the sternum (xiphoid process) by
selecting all subcutaneous voxels in the -190 to -30 HU range. Coronary
PVAT (Studies 2 and 3) was defined as all voxels in the HU range of -190
to -30 HU located within a radial distance from the outer vessel wall
equal to the diameter of the respective vessel, as previously described.16
Perivascular adipose tissue segmentation was performed around the
proximal to distal right coronary artery (RCA; anatomical segments #1, 2
and 3 based on the Society of Cardiovascular CT anatomical classifica-
tion) and the combined left main and proximal to mid left anterior
descending artery (LCA: left coronary artery; anatomical segments #5, 6,
7).29,30 The left circumflex artery was not analysed given its variable anat-
omy and small calibre, as already described in the CRISP-CT study.16
Radiomic characterization
Calculation of radiomic features was performed on contrast CCTA scans
using 3D Slicer (v.4.9.0-2017-12-18 r26813).31 For each unique AT seg-
mentation, a total of 843 radiomic features were calculated, ranging from
shape-related to first- and higher-order (texture) statistics
(Supplementary material online, Tables S5–S12), using the
SlicerRadiomics extension which incorporates the Pyradiomics library
into 3D Slicer.32 More details on segmentation, bin discretization, radio-
mic matrix symmetry, and wavelet transformations can be found in the
Supplementary material online. Fat radiomic profile was independent of
the mean arterial lumen attenuation as measured at the aortic root (Rho
= -0.005, P= 0.90), as the segmented PVAT volumes is sufficiently (>2
voxels) away from the outer wall of the coronary artery, thus the meas-
urements are not affected by the lumen partial voluming effect.
Moreover, texture radiomic phenotyping assesses the relative rather
than absolute changes in PVAT attenuation, explaining why the measure-
ments are independent of the absolute, baseline attenuation. Epicardial
adiposity and perivascular FAI (as validated in our previous work12,16)
were also quantified using dedicated software (Aquarius WorkstationVR
V.4.4.11-13, TeraRecon Inc., Foster City, CA, USA for basic segmentation
and CaRi-HEART proprietary algorithms (Caristo Diagnostics Ltd,
Oxford, UK) for final calculation), as described previously.16
Adipose tissue collection, ribonucleic acid
isolation, and gene expression studies
In Study 1, adipose tissue biopsies were harvested from the incision site
in 167 patients undergoing cardiac surgery and transferred to the lab on
ice, as previously described.12 Total ribonucleic acid (RNA) was isolated
by phenol:chloroform (1:5 ratio) separation followed by magnetic beads-
based RNA purification (using a KingFischer magnetic particle robotic
processor). RNA was reverse-transcribed to complementary deoxyribo-
nucleic acid (cDNA) by using SuperScript VILO mastermix. Quantitative
real-time polymerase chain reactions (PCR) for TNFA, COL1A1, CD31 and
PPIA (housekeeping gene), were performed by using TaqMan probes on a
QuantStudio 7 flex real-time PCR system (details in the Supplementary
material online).
Statistical analysis
Participant demographics are summarized as numbers (percentages) or
median (25th to 75th percentile) for categorical and continuous variables,
respectively (unless specified otherwise). Between-group comparisons
were performed using Pearson’s v2 or Fisher’s exact test for categorical
variables, and Mann–Whitney’s U test for continuous variables.
In Study 1, the strength of association between attenuation- and
texture-based radiomic features of AT (n= 825 after excluding 18
shape- and volume-related features) and the relative gene expression of
TNFA, COL1A1, and CD31 in respective adipose tissue biopsies was
4 E.K. Oikonomou et al.
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..summarized using Manhattan plots [-log10(P-values) of the Spearman’s
rho coefficients]. Bonferroni correction was applied by dividing the sig-
nificance level of a= 0.05 by the number of components that described
99.5% of the radiomic variation, as described elsewhere.33 In order to
assess the incremental value of texture analysis for description of adi-
pose tissue biology, stepwise multivariable linear regression models
were built with gene expression as the dependent variable and age, sex,
body mass index, hypertension, dyslipidaemia, and diabetes mellitus
(block 1), followed by the addition of mean attenuation (block 2), and
the three top principal components of the AT ‘radiome’ (block 3, F-level
cut-off of 0.05 and 0.10 for inclusion/exclusion in the model). Gene ex-
pression profiles were log-transformed prior to inclusion in the models.
The F-metric and F-test were used to assess the improvement in model
performance at each step.
In Study 2, only features with an inter-observer ICC >_0.9 were
included in all subsequent analyses (n= 15 scans analysed by two inde-
pendent analysts). Correlation plots (using the non-parametric
Spearman’s rank correlation coefficient) and a heatmap depicting the vari-
ance of the Z-score-transformed individual radiomic features across the
SCOT-HEART population are graphically presented. Further, hierarchical
clustering of the individual radiomic features was performed using the
squared Euclidean distance and the Ward method.
To address the multi-dimensionality and possible redundancy of the
radiomic dataset, the amount of pairwise correlations was reduced at the
level of jrhoj>_0.9 using the findCorrelation function of the caret package in
R. In an initial assessment of the dataset, a Manhattan plot was created
based on the value of each radiomic feature in discriminating the MACE
from the non-MACE cases [-(log10) of the P-value from univariable re-
ceiver operating characteristic (ROC) curve analysis]. Subsequently, the
nested case-control study in Study 2 was randomly split into a training/in-
ternal validation (80%) and external validation set (20%), ensuring an
equal representation of events and non-events in both splits. A random
forest method was selected to train a model to discriminate 5 year
MACE from no MACE, since it enables modelling of non-linear relation-
ships, can train on small datasets, is less sensitive to outliers and has been
previously used in patient-specific predictive modelling.34 Further details
on centring, scaling of radiomic features, recursive feature elimination, in-
ternal cross-validation, and final validation can be found in the
Supplementary material online. The final product of the random forest al-
gorithm (namely the probability of belonging to the MACE vs. no MACE
group) was defined as the FRP. The biological meaning of the most im-
portant constituent features of FRP was assessed by presenting the signifi-
cance level of association with adipose tissue fibrosis (COL1A1 relative
expression), inflammation (TNFA relative expression), and vascularity
(CD31 relative expression), as assessed in Study 1.
When applied in a cohort-wide setting in the SCOT-HEART trial, an
optimal FRP cut-off point was selected to define high- vs. low-risk groups
by identifying the value that maximizes the log-rank statistic for MACE. Its
prognostic value for (i) MACE; (ii) a composite endpoint of MACE, and
late revascularization (revascularization >_6 weeks post-CCTA; corre-
sponding to the timepoint for assessment of the certainty of coronary
heart disease diagnosis in the SCOT-HEART trial),23 and (iii) non-cardiac
mortality was then assessed in both univariable Kaplan–Meier curves and
Cox regression models adjusted for age, sex, systolic blood pressure, dia-
betes mellitus, body mass index, smoking status, presence of CAD (>_50%
stenosis), total cholesterol and high-density lipoprotein levels as well as
scanner type, presence of HRP features and Agatston CCS
[log(CCSþ 1); details in the Supplementary material online]. The incre-
mental value of FRP for prediction of MACE beyond a baseline model
consisting of the aforementioned factors was assessed by comparing the
time-dependent ROC curves of the two nested models (traditional risk
factors ± FRP) at 5 years post-CCTA.
In Study 3, the distribution of FRP between AMI and matched stable
CAD patients was compared using the non-parametric Mann–Whitney U
test. The changes in FAI or FRP between baseline and follow-up were
assessed using a paired, non-parametric Wilcoxon-signed rank test. On
the other hand, changes in FAI along a culprit lesion at baseline (within
96 h after AMI) and at 6 months were compared with a repeated meas-
ures two-way analysis of variance test with timepoint  length
interaction.
Statistical analyses were performed in the R environment (R version
3.4 and R Studio version 1.1.453) and using IBM SPSS Statistics for
Windows (Version 22.0. IBM Corp. Released 2013. Armonk, NY, USA).
All tests were two-sided and a was set at 0.05, unless specified otherwise.
Results
Adipose tissue radiomic characteristics
for detection of tissue inflammation,
fibrosis and vascularity (Study 1)
Radiotranscriptomic analysis of human adipose tissue revealed that
wavelet-transformed mean attenuation (a first-order statistic which
forms the basis of the FAI) was the best-performing metric for detec-
tion of adipose tissue inflammation, as assessed by the relative ex-
pression of TNFA (Figure 2A). However, higher-order statistics
reflecting the radiomic texture of adipose tissue on CT imaging had
comparable or even higher accuracy than mean attenuation (Figure
2B, C) in detecting fibrosis and vascularity, as assessed by the relative
expression of COL1A1 (collagen type 1 alpha 1 chain) and the
endothelial-marker CD31 (platelet-endothelial cell adhesion
molecule-1). In multivariable analysis, inclusion of the three principal
components of the adipose tissue ‘radiome’ (Figure 2D) improved
the predictive value of a model including clinical risk factors and
mean attenuation to detect adipose tissue fibrosis and vascularity,
but not inflammation (Figure 2E). This proof-of-concept analysis
suggests that texture phenotyping of adipose tissue provides a
non-invasive means to detect fibrosis and adipose tissue micro-
vascular remodelling.
Searching for a radiomic signature in
perivascular adipose tissue that
predicts cardiac risk beyond attenuation
(Study 2a)
Radiomic phenotyping of coronary PVAT around the RCA and LCA
produced a total of 1686 radiomic features (843 features around
each vessel; Supplementary material online, Figure S1 and Figure 2A).
Stability analysis identified 1391 (82.0%) features with an ICC >_ 0.9
(Supplementary material online, Figure S2). A correlation plot with
further hierarchical clustering of these stable 1391 radiomic features
in 1575 SCOT-HEART patients revealed distinct clusters of highly
correlated features (Figure 3B), with notable variance across the co-
hort population (Figure 3C).
A total of 101 MACE cases (within 5 years of CCTA) and 101
matched controls with MACE-free 5 years of follow-up
(Supplementary material online, Table S2) were retrieved from the
discovery CCTA pool and used in a case-control study to identify the
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.presence of a distinct radiomic signature that is independently associ-
ated with cardiac risk (Figure 4). The two groups were well-matched
for age, traditional cardiovascular risk factors, systemic or epicardial
obesity and CT scanning parameters (Supplementary material online,
Table S2). In univariable ROC analysis, a total of 22 (1.6%), 86 (6.2%)
and 241 (17.3%) of the 1391 stable radiomic features were found to
discriminate MACE from non-MACE cases (P< 0.001, P< 0.01, and
P< 0.05, respectively; Figure 5A).
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Figure 2 Radiomic phenotyping to detect biological hallmarks of dysfunctional adipose tissue. (A–C) Manhattan plots presenting the strength of as-
sociation [-log10(P-value) of Spearman’s rho] between adipose tissue radiomic features and the relative gene expression of TNFA (inflammation),
COL1A1 (fibrosis), and CD31 (endothelial marker, vascularity)*. Radiomic features were split into two groups, consisting of first-order statistics (green
colour, derived from simple attenuation histogram analysis) or higher-order statistics (red colour, reflecting the radiomic texture and spatial interrela-
tion of voxels). The dotted line represents the Bonferroni-adjusted significance level (a= 0.00068). (D) Component plot of the three principal com-
ponents of the adipose tissue radiome. (E) Comparison of nested linear regression models with relative gene expression as the dependent variable
and (i) clinical risk factors alone (Model 1: age, sex, hypertension, hypercholesterolaemia, diabetes mellitus, body mass index); (ii) Model 1þMean
Attenuation (Model 2); and (iii) Model 2þ PVAT radiome (first three principal components) as the independent predictors. The F statistic at each
step is presented and compared with the previous step using the F-test. Imc, informational measure of correlation 2; L/H, low/high wavelet transform-
ation; SALGLE, small area low grey level emphasis; SDLGLE, small dependence low grey level emphasis; SRHGLE, Short Run Low Grey Level
Emphasis. *Relative gene expression was calculated using cyclophilin A (PPIA) as the housekeeping gene.
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In order to identify a single radiomic signature that combines the
diagnostic value of all these features, the study population was ran-
domly split into a training/internal validation (80%) and an external
validation set (20%; Figure 4). Reduction of pairwise correlations at
the level of jSpearman’s rhoj>_0.9 resulted in 335 independent fea-
tures. Recursive feature elimination with a random forest algorithm
and repeated five-fold cross-validation showed a plateau in the accur-
acy of the trained model with a selection of 64 features
(Supplementary material online, Figure S3). Following three rounds of
repeated five-fold cross-validation in order to validate the best-
performing model internally and avoid overfitting, the discriminatory
value of the model (FRP) was confirmed in the remaining validation
set [AUC 0.774 (95% CI 0.622–0.926)] (Figure 5B and Supplementary
material online, Figure S4).
To understand the biological interpretation of FRP, we then
searched for the overlap between the radiotranscriptomic signatures
for adipose tissue inflammation, fibrosis and vascularity and the
features included in the FRP (Figure 5C). Notably, FRP consists of a
range of PVAT radiomic features that are differentially associated
with either inflammation, fibrosis and vascularity or any combination
of these hallmarks of dysfunctional adipose tissue.
Exploring the prognostic value of the fat
radiomic profile in SCOT-HEART (Study
2b)
We next determined the FRP signature in the 1575 eligible CCTA
scans from the SCOT-HEART study. Over a median follow-up
period of 4.8 (25th to 75th percentile: 4.2–5.7) years, one confirmed
cardiac death, 33 non-fatal AMI events, 176 late revascularization
events and 32 non-cardiac death events were recorded
(Supplementary material online, Table S3). FRP was positively associ-
ated with the adjusted risk of MACE [per 0.01 increments: adj. HR
1.12 (95% CI 1.08–1.15), P< 0.001]. For an optimal cut-off point of
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Figure 3 Radiomic phenotyping of coronary perivascular adipose tissue. (A) The perivascular adipose tissue of the right and left coronary arteries
(left main and proximal to mid left anterior descending artery) was segmented and used to calculate a number of shape-, attenuation-, and texture-
related statistics. (B) Correlation plot of all 1391 stable radiomic features in the SCOT-HEART population (n= 1575 patients), with hierarchical clus-
tering revealing distinct clusters of radiomic variance. (C) Heatmap of scaled radiomic features in the SCOT-HEART population revealing between-
patient variance across the cohort. LCA, left coronary artery; PVAT, perivascular adipose tissue; RCA, right coronary artery.
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0.63 (Supplementary material online, Figure S5) individuals with FRP >_
vs. <0.63 (FRPþ vs. FRP-) had a 10.8-fold higher risk of MACE, after
adjustment for age, sex, SBP, total cholesterol, HDL, diabetes melli-
tus, smoking, BMI, obstructive disease, scanner type, presence of
HRP features, and calcium score (Figure 6A). Of note, FRP was not
related to the presence of HRP features (Rho = 0.004, P= 0.87), and
correlated very weakly with calcium score (rho = 0.07, P= 0.007).
FRPþ/HRPþ individuals had a 43-fold higher risk of MACE compared
with the FRP-/HRP- participants, after adjustment for age, sex, SBP,
total cholesterol, HDL, diabetes mellitus, smoking, BMI, and scanner
type (Figure 6B). FRP significantly improved the predictive value of a
traditional model consisting of age, sex, systolic blood pressure, dia-
betes mellitus, body mass index, smoking status, presence of CAD
(>_50% stenosis), total cholesterol, high-density lipoprotein levels,
scanner type, presence of HRP, as well as Agatston CCS
[log(CCSþ 1); Figure 6C]. In further analyses, FRP did not predict
non-cardiac mortality (Figure 6D) but remained an independent pre-
dictor of a composite endpoint of MACE or late coronary revascula-
rization (>_6 weeks post-CCTA; Figure 6E, F) confirming the cardiac-
specific nature of the biomarker.
Pericoronary fat radiomic profile in acute
myocardial infarction (Study 3)
Radiomic phenotyping of 44 AMI patients scanned within 96 hours of
admission and 44 matched controls undergoing clinical CCTA for
CCTA pool (n=5487)
MACE within 5 years:
Training & Internal validation cohort 
5-fold (x3) cross-validation
(internal validation)
Controls:
External validation cohort
80% 20%
FRP signature
1:1 Matching
External validation 
Test of cohort-wide performance
of FRP signature 
in SCOTHEART
(residual cardiac risk prediction)
Figure 4 Identifying the high-risk pericoronary fat radiomic profile (Study 2). Cases of individuals that suffered a major adverse cardiac events (car-
diac death or non-fatal myocardial infarction) within 5 years of their coronary CT angiography scan (n= 101) and matched controls (n= 101) were
selected from a pool of 5487 individual coronary CT angiography scans with follow-up for outcomes. These were randomly split into a training and
internal validation set (80% of observations and events, using repeated five-fold cross-validation) and an external validation set (the remaining 20%)
to train and test a random forest model to discriminate MACE from non-MACE cases. The product of the random forest model was defined as the
fat radiomic profile. The FRP was subsequently measured in 1575 consecutive eligible cases from the SCOT-HEART study to assess its cohort-wide
performance in predicting the residual cardiac risk among individuals undergoing clinically indicated coronary CT angiography. CCTA, coronary com-
puted tomography angiography; FRP, fat radiomic profile; MACE, major adverse cardiac events.
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.stable CAD revealed higher FRP values (consistent with adverse
PVAT remodelling) in the AMI vs. the control group (Figure 7A), des-
pite no differences in demographics, clinical risk factors or medica-
tions (Supplementary material online, Table S4).
Finally, in a subgroup of 16 patients who underwent sequential
CCTA scanning within 96 hours of admission for AMI and 6 months
later, no significant changes were observed in FRP. In contrast,
perivascular FAI around the RCA, a specific biomarker of the overall
coronary inflammation, changed dynamically at 6 months (Figure 7B).
In a subgroup of 10 patients with STEMI, these changes were particu-
larly pronounced in the region directly adjacent to the culprit lesion,
demonstrating significant changes in local FAI and the FAI-defined pla-
que inflammatory burden at 6 months (Figure 7C, D). These findings
further support the notion that FAI flags reversible, dynamic changes
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Figure 5 The pericoronary fat radiomic profile. (A) A forest plot of the discriminatory value of each radiomic feature in univariable analysis. (B)
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Figure 6 Prognostic value of the pericoronary fat radiomic profile. (A, B) Kaplan–Meier curves and adjusted hazard ratios for major adverse cardiac
events across strata of fat radiomic profile [>_0.63 (FRPþ) vs. 0.63 (FRP-)] and high-risk plaque features. (C) Time-dependent receiver operating char-
acteristic curves (t= 5 years post-coronary CT angiography) for two nested prediction models consisting of age, sex, systolic blood pressure, diabetes
mellitus, body mass index, smoking status, presence of coronary artery disease (>_50% stenosis), total cholesterol, high-density lipoprotein levels,
scanner type, presence of high-risk plaque, as well as Agatston coronary calcium scoring [log(CCSþ 1)] with (AUC: 0.880) or without (AUC: 0.754)
FRP. (D) Kaplan–Meier curves and adjusted hazard ratios for non-cardiac mortality, as well as a composite endpoint of major adverse cardiac events
and/or late revascularization (E, F) across strata of FRP and high-risk plaque features. AUC, area under the curve; CI, confidence interval; CCS, coron-
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MACE, major adverse cardiac events.
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.in PVAT composition (e.g. adipocyte size and lipid accumulation),
whereas FRP complements this information with detection of more
advanced, irreversible changes, such as adipose tissue vascularity and
fibrosis.
Discussion
The recent development of the perivascular FAI, a CCTA-derived
biomarker of coronary inflammation based on quantification of
PVAT attenuation shifts, highlights the potential for complementary
imaging biomarkers that can describe the full phenotypic heterogen-
eity of PVAT composition and remodelling and its clinical importance.
Using a radiotranscriptomic approach, we now demonstrate that
specific texture patterns within the radiomic profile of PVAT de-
scribe fibrosis and vascularity, reflecting permanent changes in adi-
pose tissue induced by chronic coronary inflammation.17 Following
this discovery, we used machine learning to build a new radiomic sig-
nature of high-risk PVAT around the coronary arteries, namely the
perivascular FRP, that relies on detection of such changes to identify
individuals at increased cardiac risk. Application of this method in the
SCOT-HEART trial revealed an association between adverse coron-
ary PVAT remodelling captured by FRP and residual cardiac risk.
Contrary to FAI, which changes dynamically and can be used to pro-
spectively monitor responsiveness to risk reduction measures, FRP
detects persistent adverse structural remodelling in PVAT and an
associated residual risk not confounded by concomitant medications
or other acute processes (Take home figure).
Perivascular adipose tissue as a sensor of
vascular biology
We have recently discovered that vascular inflammation drives
changes in PVAT, due to inside-to-outside signals released from the
vascular wall.12–15 A new imaging biomarker, the perivascular FAI,
detects vascular inflammation by capturing spatial shifts in PVAT
composition and lipid content as CT attenuation gradients around
the coronary arteries.12 The FAI was recently validated in the CRISP-
CT study,16 where it was found to have prognostic value for all-cause
and cardiac-related mortality. However, FAI appeared to lose its
prognostic value in a sub-population of the CRISP-CT study which
started treatment with statins and aspirin post-CCTA, suggesting that
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Figure 7 Pericoronary fat radiomic profile in acute myocardial infarction. (A) Tukey box-plot of FRP values in patients scanned within 96 h of acute
myocardial infarction and matched controls undergoing clinical coronary CT angiography for suspected stable coronary artery disease (n= 44 per
group). (B) FRP and perivascular Fat Attenuation Index in acute myocardial infarction patients scanned within 96 hours of admission and 6 months
later (n= 16 per group). (C) In a subgroup of patients with ST-elevation myocardial infarction (STEMI) at baseline, Fat Attenuation Index changes
were particularly pronounced in the region directly adjacent to the culprit lesion (n= 10). (D) Change in Fat Attenuation Index-associated inflamma-
tory burden, defined as the area under the curve of Fat Attenuation Index measured along a given culprit lesion within 96 h of an acute ST-segment
elevation myocardial infarction (STEMI) and 6 months later. AMI, acute myocardial infarction; AU, arbitrary units; CAD, coronary artery disease; FAI,
Fat Attenuation Index; HU, Hounsfield Units; STEMI, ST-segment elevation myocardial infarction. P-values derived from Mann–Whitney U test (A),
Wilcoxon-signed rank test (B, D) and two-way repeated measures analysis of variance with timepoint/distance interaction (C).
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the risk identified by FAI may be modifiable.16 This led to the need for
additional biomarkers that would detect permanent changes in PVAT
composition that would be less affected by treatments targeting vas-
cular inflammation.
Discovering novel radiotranscriptomic
signatures of adverse perivascular
adipose tissue remodelling
Imaging studies in oncology have shown that specific shape- and
texture-related patterns generate tumour phenotypes that are inde-
pendently linked to the underlying tumour biology and to clinical
prognosis.35 Such patterns, often derived from complex mathematic
formulae, are invisible to the naked eye of experienced radiologists
and clinicians.36 Radiomic approaches map these qualitative imaging
features and generate a number of quantitative variables that describe
the imaged structure. In a recent study, Kolossvary et al.33 showed
that radiomic features can reliably identify HRPs with napkin-ring sign
and discriminate metabolically active from inactive lesions.37
Radiomic analysis of adipose tissue is another novel method that
requires investigation.
Further to lipolysis, reduced adipogenesis and water accumulation
within PVAT, vascular inflammation also triggers more permanent
changes in the perivascular space, such as fibrosis and
neoangiogenesis,17,18 which could also be captured by CCTA. In a
radiotranscriptomic experiment using adipose tissue biopsies from
167 patients undergoing cardiac surgery, we searched for radiomic
features that would best describe the gene expression of TNFA
(marker of inflammation), COL1A1 (marker of fibrosis), and CD31
(marker of vascularity). Indeed, as expected,12 features describing adi-
pose tissue attenuation (captured by the FAI) were the most descrip-
tive of TNFA expression. However, features associated with the
radiomic texture of adipose tissue enabled a more accurate detection
of more permanent changes in its phenotype, such as fibrosis (COLA1
expression) and microvascular remodelling (endothelial-marker
CD31 expression) that affect the histological (and therefore radio-
mic) heterogeneity of adipose tissue. Of note, different radiomic pat-
terns were differentially associated with tissue inflammation, fibrosis,
and vascularity, suggesting that a comprehensive radiomic phenotyp-
ing approach is needed to accurately describe the biological variation
of human adipose tissue.
Developing and validating the high-risk
fat radiomic profile
In a discovery study that included individuals who developed a MACE
within 5 years from the CCTA and matched controls, we applied a
machine learning-based approach with multiple rounds of validation,
Healthy vessel Early inﬂammaon Chronic inﬂammaon
Reversible Irreversible
↓ Lipid/water balance
↑ Fibrosis & vascularity
↓ Tissue homogeneity
↑ Lipid/water balance
Minimal ﬁbrosis & vascularity
↑ Tissue homogeneity
↓ Lipid/water balance
Low ﬁbrosis & neovascularizaon
↑ Tissue homogeneity
FAI: low high
low highFRP:
adverse 
PVAT 
remodelling
Take home ﬁgure Fat radiomic profile as a marker of adverse perivascular adipose tissue remodelling. Coronary inflammation is associated
with phenotypic changes in perivascular adipose tissue, characterized by decreased adipocyte size and intracellular lipid accumulation. This phenotyp-
ic shift forms the basis of the CT-derived Fat Attenuation Index that characterizes attenuation changes in perivascular adipose tissue. However,
chronic vascular inflammation and atherosclerotic disease are associated with further, irreversible changes in perivascular adipose tissue composition,
such as increased extracellular fibrosis and microvascular remodelling. Those changes can now be detected by analysing the radiomic phenotype of
perivascular adipose tissue on coronary CT angiography imaging. A comprehensive analysis of volumetric, attenuation-based and texture-based met-
rics of coronary perivascular adipose tissue on coronary CT angiography imaging carries incremental prognostic value in cardiac risk prediction and
highlights the critical role of perivascular adipose tissue in human atherosclerotic cardiovascular disease. CCTA, coronary computed tomography
angiography; FAI, Fat Attenuation Index; FRP, fat radiomic profile; PVAT, perivascular adipose tissue.
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which enabled us to discover a high-risk PVAT radiomic profile (FRP)
that is linked to increased cardiac risk. Importantly, FRP offered incre-
mental prognostic information beyond current CCTA-based tools
(including Agatston CCS, HRP features and luminal stenosis), suggest-
ing a residual level of cardiac risk that is not detected by traditional
risk stratification algorithms. This signature captured not only the at-
tenuation features included in FAI but also features capturing fibrosis
and vascularity of PVAT. To see whether this radiomic signature cap-
tures permanent changes induced by chronic inflammation in PVAT,
the high-risk signature (FRP) was applied in the CCTA arm of the
SCOT-HEART trial. This population had CCTA-guided management,
with many risk-modifying interventions post-CCTA, thus affecting
the clinical value of their baseline FAI measurement. Despite this, we
observed that FRP retained its prognostic value for future MACE,
with incremental value beyond the current state-of-the-art in CCTA-
based risk prediction.
Fat radiomic profile and acute
myocardial infarction
Chronic inflammation leads to accelerated atherogenesis and induces
plaque instability leading to acute coronary syndromes.8 In further
analysis, FRP analysis revealed adverse PVAT remodelling in patients
presenting with AMI compared with matched controls with stable
disease. After performing serial CCTA scans in patients with AMI,
FRP remained unchanged, whereas FAI was significantly decreased
following 6 months of optimal medical therapy. These findings sug-
gest that FRP (a patient-specific index) may be a useful biomarker for
first-time screening of individuals undergoing CCTA, whereas FAI (a
segment or plaque-specific index) captures the dynamic inflammatory
burden of the coronary vasculature and can be used to track longitu-
dinal changes in coronary inflammation.
Limitations
The limited number of adverse events in the SCOT-HEART popula-
tion (34 MACE events over a median follow-up of 4.8 years), which is
typical of a low-risk patient cohort undergoing CCTA, means that
further testing in independent cohorts may be needed to refine and
calibrate the radiomic models. This will be facilitated by the develop-
ment of automated software solutions which will reduce the compu-
tationally heavy, long analysis times required with current software.
Currently, analysis time for full segmentation and radiome profile ex-
traction takes 45 min per patient. New applications under way will
use online Graphics Processing Units (GPU) in a cloud environment,
automating detection of the coronary arteries and pericardium, peri-
vascular space segmentations, feature extraction for calculation of
FRP/FAI, with simultaneous corrections for all the other technical
and anatomical information needed for artificial intelligence (AI)-
based proprietary algorithms to perform the whole process, which is
expected to last <5 min per patient. Also, due to the variable anat-
omy of the left circumflex coronary artery, analysis of FRP around
that artery was not performed in this study. Future research in larger
cohorts is needed, to allow reliable application of fat radiomic profil-
ing around the left circumflex artery.16 In addition, intracoronary
imaging studies38,39 may be needed to better characterize the associ-
ation of PVAT radiome with coronary atherosclerosis phenotype, in
our effort to identify the ‘unstable plaque’ and ultimately the ‘unstable
patient’. Finally, a critical validation study (VIP study; Validation study
for introduction of novel computed tomography Imaging biomarkers
in clinical Practice, Oxford RECA/19/SC/0273) is currently underway
aiming to provide the necessary adjustment factors for the interpret-
ation of quantitative CT biomarkers across a range of hardware and
scan/reconstruction settings.
Conclusions
We present a high-risk radiomic signature of coronary PVAT, derived
from machine learning-based analysis of traditional CCTA scans,
which detects adverse structural changes associated with PVAT fi-
brosis and microvascular remodelling. FRP significantly improves risk
prediction for adverse clinical events beyond the current state-of-
the-art and discriminates patients with AMI from those with stable
disease. Whereas FAI (attenuation) changes dynamically in response
to acute coronary inflammation, FRP (radiomic texture) captures
more permanent structural changes in PVAT and provides additional
risk stratification. The combination of FAI (a component of FRP) and
FRP facilitates the development of a more comprehensive individual-
ized cardiac risk profile for each patient. In conclusion, radiomic char-
acterization of PVAT by means of the FRP is a novel, promising
approach to capture adverse PVAT remodelling around the coronary
arteries and its associated residual cardiac risk.
Supplementary material
Supplementary material is available at European Heart Journal online.
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